ABVC BIOPHARMA INC (ABVC)
US00091F3047 - Common Stock
Taking everything into account, ABVC scores 1 out of 10 in our fundamental rating. ABVC was compared to 587 industry peers in the Biotechnology industry. Both the profitability and financial health of ABVC have multiple concerns. While showing a medium growth rate, ABVC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ABVC has reported negative net income.
ABVC had a negative operating cash flow in the past year.
In the past 5 years ABVC always reported negative net income.
ABVC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ABVC (-72.51%) is worse than 67.86% of its industry peers.
The Return On Equity of ABVC (-125.28%) is worse than 61.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.51% | ||
| ROE | -125.28% | ||
| ROIC | N/A |
ROA(3y)-110.94%
ROA(5y)-93.93%
ROE(3y)-266.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ABVC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABVC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABVC has been increased compared to 1 year ago.
ABVC has more shares outstanding than it did 5 years ago.
ABVC has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -7.41, we must say that ABVC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.41, ABVC is not doing good in the industry: 71.79% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.11 indicates that ABVC is not too dependend on debt financing.
ABVC has a Debt to Equity ratio of 0.11. This is in the lower half of the industry: ABVC underperforms 63.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.41 |
ROIC/WACCN/A
WACC8.17%
2.3 Liquidity
A Current Ratio of 0.28 indicates that ABVC may have some problems paying its short term obligations.
ABVC has a Current ratio of 0.28. This is amonst the worse of the industry: ABVC underperforms 97.44% of its industry peers.
ABVC has a Quick Ratio of 0.28. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
ABVC's Quick ratio of 0.28 is on the low side compared to the rest of the industry. ABVC is outperformed by 97.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.28 |
3. Growth
3.1 Past
ABVC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.84%, which is quite impressive.
The Revenue for ABVC has decreased by -83.71% in the past year. This is quite bad
Measured over the past years, ABVC shows a very strong growth in Revenue. The Revenue has been growing by 72.43% on average per year.
EPS 1Y (TTM)51.84%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q68.3%
Revenue 1Y (TTM)-83.71%
Revenue growth 3Y-31.78%
Revenue growth 5Y72.43%
Revenue growth Q2Q-99.63%
3.2 Future
The Earnings Per Share is expected to decrease by -28.17% on average over the next years. This is quite bad
ABVC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 245.77% yearly.
EPS Next Y-57.14%
EPS Next 2Y-28.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y245.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ABVC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABVC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ABVC's earnings are expected to decrease with -28.17% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.17%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ABVC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ABVC BIOPHARMA INC
NASDAQ:ABVC (5/6/2024, 8:54:54 AM)
1.08
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.40M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.51% | ||
| ROE | -125.28% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.28 | ||
| Quick Ratio | 0.28 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)51.84%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-57.14%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-83.71%
Revenue growth 3Y-31.78%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y